Skip to main content
Mucopolysaccharidosis VIIRare diseaseGeneticsSkinMetabolicBones and joints

What this study is

The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.

What's being tested

  • No Intervention

    Intervention · OTHER

    Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.

Study details

Official title
Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
Sponsor
Ultragenyx Pharmaceutical Inc
Conditions
Mucopolysaccharidosis VII · MPS VII · MPS 7 · Sly Syndrome
Enrolling
50 people
Starts
2018-01-29
Est. completion
2032-04
Record
View on ClinicalTrials.gov ↗